Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
358
datasets available to search
ShareScore release 0.9.0
Dataset results
358 results for “SAR studies”
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants
ClinicalTrials.gov study NCT04505722. IPD Sharing: YES. Countries: 8. Publications: 8.
A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients
ClinicalTrials.gov study NCT04847141. IPD Sharing: NO. Countries: 1. Publications: 1.
Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
ClinicalTrials.gov study NCT01421498. IPD Sharing: Not stated. Countries: 1. Publications: 1.
COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household
ClinicalTrials.gov study NCT04452318. IPD Sharing: YES. Countries: 3. Publications: 8.
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
ClinicalTrials.gov study NCT04927065. IPD Sharing: Not stated. Countries: 1. Publications: 3.
A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Ag
ClinicalTrials.gov study NCT04652102. IPD Sharing: Not stated. Countries: 10. Publications: 1.
A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2
ClinicalTrials.gov study NCT05113862. IPD Sharing: YES. Countries: 1. Publications: 1.
Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)
ClinicalTrials.gov study NCT01024608. IPD Sharing: Not stated. Countries: 1. Publications: 1.
SARS-CoV-2 Human Challenge Characterisation Study
ClinicalTrials.gov study NCT04865237. IPD Sharing: NO. Countries: 1. Publications: 4.
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
ClinicalTrials.gov study NCT04497987. IPD Sharing: YES. Countries: 1. Publications: 4.
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)
ClinicalTrials.gov study NCT04283461. IPD Sharing: Not stated. Countries: 1. Publications: 8.
Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR
ClinicalTrials.gov study NCT00854360. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence
ClinicalTrials.gov study NCT05205746. IPD Sharing: YES. Countries: 1. Publications: 57.
Breakthrough SARS-CoV-2 outcomes in immune-disordered people during the Omicron era: A prospective cohort study
Open the record for dataset details and reuse information.
SARS-CoV-2 transmission and control in a hospital setting: an individual-based modelling study
Open the record for dataset details and reuse information.
Evaluation of oxidative stress markers in Rwanda during the SARS-CoV-2 pandemic: a cross-sectional study
Open the record for dataset details and reuse information.
Effectiveness of Inactivated SARS-CoV-2 Vaccine (CoronaVac) on Survival at Intensive Care Unit: A Cross-sectional Study
<p><em>Background: </em>This study compared the course of COVID-19 in vaccinated and unvaccinated patients admitted to an intensive care unit (ICU) and evaluated the effect of vaccination with CoronaVac on admission to ICU.</p> <p><em>Methods: </em>Patients admitted to ICU due to COVID-19 between 1 April 2021 and 15 May 2021 were enrolled to the study. Clinical, laboratory, radiological parameters, hospital and intensive care unit mortality were compared between vaccinated patients and eligible but unvaccinated patients. Patients over 65 years old were the target population of the study due to the national vaccination schedule.</p> <p><em>Results: </em>Data from 90 patients were evaluated. Of these, 36 (40.0%) were vaccinated. All patients had the CoronaVac vaccine. Lactate dehydrogenase and ferritin levels were higher in unvaccinated group than vaccinated group (p=0.021 and 0.008, respectively). SpO<sub>2</sub> from the first arterial blood gas at ICU was 83.71±19.50 % in vaccinated, 92.36±6.59 % in unvaccinated patients (p=0.003). Length of ICU and hospital stay were not different (p=0.204, 0.092, respectively). ICU and hospital mortality were similar between groups <strong>(<strong>p=0.11 and 0.70, respectively</strong>).</strong></p> <p><em>Conclusions: </em>CoronaVac vaccine had no effect on survival from COVID-19. CoronaVac’s protective effect, especially on new genetic variants, should be investigated further.</p>
Public attitudes to a human challenge study with SARS-CoV-2: a mixed-methods study
<p>Human challenge studies involve the deliberate exposure of healthy volunteers to an infectious micro-organism in a highly controlled and monitored way. They are used to understand infectious diseases and have contributed to the development of vaccines. In early 2020, the UK started exploring the feasibility of establishing a human challenge study with SARS-CoV-2. Given the significant public interest and the complexity of the potential risks and benefits, it is vital that public views are considered in the design and approval of any such study and that investigators and ethics boards remain accountable to the public.</p> <p>We conducted a mixed methods study comprising online surveys conducted with 2,441 UK adults and in-depth virtual focus groups with 57 UK adults during October 2020 to explore the public’s attitudes to a human challenge study with SARS-CoV-2 taking place in the UK.</p> <p>This depositary includes:</p> <ul> <li>Documentation relating to the online surveys; <ul> <li>Survey</li> <li>Animation that survey participants were asked to view</li> <li>Survey wrappers (invitations, participant information sheet and consent, end of survey messages)</li> <li>Survey data (demographic information not included)</li> </ul> </li> <li>Documentation relating to focus groups: <ul> <li>Participant Information Sheet</li> <li>Focus Group Discussion guide</li> </ul> </li> </ul>
Serial seroprevalence study: follow-up of immunity to SARS-Cov-2 infection and monitoring of effective vaccination coverage, in three Chilean cities
<p>Population-based serosurvey in Santiago, Talca, and Coquimbo–La Serena </p>
Transmission Dynamics of COVID-19 Disease among household contacts in Delhi, India (SARS CoV-2 HT Study)
<p>Results from households in the MAMC Delhi FFX Unity study </p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.